Status:
COMPLETED
Nerivio Efficacy by Time of Treatment Onset
Lead Sponsor:
Theranica
Conditions:
Migraine
Acute Treatment of Migraine
Eligibility:
All Genders
8+ years
Phase:
PHASE4
Brief Summary
This is a Post-marketing study investigating the impact of treatment time onset with Nerivio on the efficacy of Remote Electrical Neuromodulation (REN) for the acute treatment of migraine. Efficacy w...
Detailed Description
The REN device (Nerivio by Theranica, ISRAEL) is a neuromodulation device approved by the FDA for acute and/or preventive treatment of migraine in patients 8 years old and above. It is a wearable devi...
Eligibility Criteria
Inclusion
- • Users who had reported treatment onset time in at least one treatment through the REN companion smartphone app
Exclusion
- • Treatments that included medications for acute treatment of migraine
Key Trial Info
Start Date :
May 7 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 15 2025
Estimated Enrollment :
55261 Patients enrolled
Trial Details
Trial ID
NCT06976723
Start Date
May 7 2025
End Date
June 15 2025
Last Update
July 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Theranica Bio-Electronics Inc
Bridgewater, New Jersey, United States, 08807